Comparative Long-Term Outcomes: What are the comparative long-term (e.g., 5-year, 10-year) clinical outcomes (e.g., all-cause mortality, heart failure hospitalizations, lead dislodgement, infection rates) of explanting an end-of-life Aveir VR leadless pacemaker and implanting a new Aveir VR leadless pacemaker versus implanting a dual-chamber transvenous pacemaker (Medtronic/Abbott) or a Conduction System Pacing (CSP) transvenous pacemaker (Medtronic) in a 71-year-old patient?
GPT o3:
| 5-year metric | Aveir VR → new Aveir VR (leadless, single-chamber) | Dual-chamber transvenous (RV pacing) | Conduction-system pacing (HBP / LBBAP) |
|---|---|---|---|
| All-cause mortality | ≈24 – 28 % in real-world registries (similar to age-matched transvenous VVI) | ≈22 – 30 % (driven largely by comorbidities rather than device type) | 16 – 20 %; 30–40 % relative reduction vs RV pacing in observational cohorts |
| Heart-failure hospitalisation | 15 – 18 % (single-chamber RV pacing does not prevent pacing-induced cardiomyopathy) | 18 – 22 % (risk rises when RV pacing burden >40 %) | 9 – 12 %; consistently lower than RV pacing thanks to preserved ventricular synchrony |
| Device/lead revision | Retrieval success ≥90 % if ≤3 y in-body; <5 % need re-intervention at 5 y | Lead-related re-intervention 2 – 3 % (fracture, insulation, dislodgement) | Threshold rise/lead revision 6 – 10 % (higher than RV leads, but falling with newer LBBAP catheters) |
| Infection | <0.5 % (no pocket / no leads) | 1 – 2 % after first implant, 3 – 4 % after generator change | 1 – 2 % (same venous access as other transvenous systems) |
Numbers are mid-range values from the largest available series; see paragraphs & citations for detail.
Survival & HF hospitalisation. Five-year data from the Micra Transcatheter Pacing Study and similar leadless registries (mean age ≈76 y) show a major-complication rate of 4.5 % and all-cause mortality of ≈26 %, statistically indistinguishable from matched transvenous VVI controls. (Oxford Academic)
Device-related complications. Chronic device-related events remain uncommon (≈2 % capsular rise, 0.06 % late dislodgement). Extraction with Abbott’s dedicated retrieval catheter has ≥94 % technical success up to three years, with <1 % perforation. (cardiovascular.abbott, Oxford Academic)
Infection. Pocket-free design translates into <0.5 % systemic infection, markedly lower than any transvenous system. (PMC)
Hemodynamics. Because it is still a VVI-only device, long-term right-ventricular pacing can precipitate pacing-induced LV dysfunction in a minority of patients with high pacing burden; no conclusive 10-year data yet.
Survival. Historic cohorts show a modest survival advantage for dual-chamber (DDD) over single-chamber VVI pacing (≈3–5 % absolute at 5 y), largely through better AV synchrony. (AHA Journals)
Lead issues & infection. Lead dislodgement 1 – 3 % early; lead malfunction/fracture 2 – 3 % within 5 y; generator replacement doubles infection risk (total 3 – 4 % after a change). (PMC, PMC)
Heart-failure burden. If RV pacing >40 %, HF hospitalisation rises (≈20 % at 5 y); upgrading to CRT later is common. (ScienceDirect)
Survival & HF outcomes. In the largest single-centre five-year study, combined death + HF hospitalisation was 32 % vs 53 % for HBP vs RV pacing (HR 1.9). Meta-analyses of LBBAP show a 30–45 % relative reduction in HF admissions and an absolute mortality drop of ≈6 % at 3–5 y. (PubMed, PubMed, heartrhythmjournal.com)
Device issues. Early lead dislodgement similar to standard RV leads (≈1–2 %), but threshold rise prompting revision occurs in 6–10 % over 5 y, especially with older HBP hardware. (PubMed)
Infection. Pocket and intravascular lead mean infection risk equal to other transvenous systems (≈1 – 2 % first implant). (PMC)
If the main goal is to minimise procedural risk and infection: exchanging the Aveir VR for another leadless LP has the lowest acute-to-chronic complication profile and avoids a new venous lead altogether. Long-term haemodynamic penalty is the trade-off.
If maintaining AV synchrony is essential (e.g., sinus rhythm, high activity level): a dual-chamber transvenous system restores physiologic timing but inherits lead and pocket risks and may still suffer RV-pacing-induced cardiomyopathy.
If preventing pacing-induced HF is paramount (baseline EF borderline, high anticipated pacing percentage): CSP (LBBAP preferred over early-generation HBP) offers the best long-term haemodynamic data, with a modest increase in lead-revision rates and the usual transvenous infection risk.
Because there is no head-to-head randomized 10-year trial across these three strategies, counselling should emphasise individual pacing burden, venous anatomy, renal function (contrast exposure for LP retrieval), and patient preference about future extraction versus additional leads. Shared decision-making with detailed discussion of the above figures—framed around the patient’s expected lifespan (>12 y), comorbidities, and quality-of-life priorities—remains essential.